马明福, 余丽, 马志萍, 张巍, 崔文丽. 侵袭性B细胞淋巴瘤中PIK3CA扩增和PTEN缺失及其临床病理学意义[J]. 中国肿瘤临床, 2018, 45(8): 379-384. DOI: 10.3969/j.issn.1000-8179.2018.08.060
引用本文: 马明福, 余丽, 马志萍, 张巍, 崔文丽. 侵袭性B细胞淋巴瘤中PIK3CA扩增和PTEN缺失及其临床病理学意义[J]. 中国肿瘤临床, 2018, 45(8): 379-384. DOI: 10.3969/j.issn.1000-8179.2018.08.060
shu
Ma Mingfu, Yu Li, Ma Zhiping, Zhang Wei, Cui Wenli. PIK3CA amplification and PTEN deletion in invasive B-cell lymphoma and their clinicopathological significance[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 45(8): 379-384. DOI: 10.3969/j.issn.1000-8179.2018.08.060
Citation: Ma Mingfu, Yu Li, Ma Zhiping, Zhang Wei, Cui Wenli. PIK3CA amplification and PTEN deletion in invasive B-cell lymphoma and their clinicopathological significance[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 45(8): 379-384. DOI: 10.3969/j.issn.1000-8179.2018.08.060
shu

侵袭性B细胞淋巴瘤中PIK3CA扩增和PTEN缺失及其临床病理学意义

PIK3CA amplification and PTEN deletion in invasive B-cell lymphoma and their clinicopathological significance

    摘要
  • 摘要:
      目的  探讨侵袭性B细胞淋巴瘤在PI3K/Akt/mTOR信号通路中PIK3CA与10号染色体上缺失的磷酸酶和张力蛋白同源物（phosphate and tension homology deleted on chromsome ten，PTEN）的表达情况及其与各临床病理指标的相关性。
      方法  回顾性分析新疆医科大学第一附属医院2008年1月至2012年12月术前未经任何治疗的侵袭性B细胞淋巴瘤标本235例，其中包括弥漫大B细胞淋巴瘤（diffuse large B-cell lymphoma，DLBCL）205例，伯基特淋巴瘤（Burkitt lymphoma，BL）27例，灰区淋巴瘤（介于DLBCL和BL之间，不能分类的B细胞淋巴瘤）3例。应用荧光原位杂交技术检测所有样本PIK3CA和PTEN基因的表达情况，统计分析其与各临床病理指标及预后的关系。
      结果  PIK3CA在侵袭性B细胞淋巴瘤中扩增率为12.3%（29/235），临床分期Ⅰ~Ⅱ期和Ⅲ~Ⅳ期的阳性率分别为8.6%（12/139）和17.7%（17/96），差异具有统计学意义（P=0.038）。PTEN在侵袭性B细胞淋巴瘤中的缺失率为13.6%（32/235），与其他临床病理特征无相关性。PIK3CA扩增和PTEN缺失呈负相关（P=0.046）。未发现PIK3CA扩增和PTEN缺失与生存期存在相关性。
      结论  PIK3CA扩增与侵袭性B细胞淋巴瘤疾病晚期相关，PIK3CA扩增和PTEN缺失在侵袭性B细胞淋巴瘤的发生中起促进作用。

     

    Abstract:
      Objective  To investigate the expression of PIK3CA and PTEN in PI3K/Akt/mTOR signaling pathway and its correlation with clinicopathological parameters in invasive B-cell lymphoma.
      Methods  A total of 235 invasive B-cell lymphoma cases enrolled in First Affliated Hospital of Xinjiang Medical University from January 2008 to December 2012, without any pre-operative treatment, were collected; those included 205 cases of diffuse large B-cell lymphoma (DLBCL), 27 cases of Burkitt lymphoma (BL), and the remaining three cases were somewhere between DLBCL and BL, but could not be classified clearly. The expression of PIK3CA and PTEN genes was detected by fluorescence in situ hybridization. The relationship between PIK3CA and PTEN genes was analyzed statistically and extended to clinicopathological parameters and prognosis.
      Results  The positive rate of PIK3CA amplification in invasive B-cell lymphoma was 12.3% (29/235), and the positive rate of clinical stageⅠ-Ⅱ (8.6%, 12/139) was much lower than that of Ⅲ-Ⅳ (17.7%, 17/96), with the difference being statistically significant (P=0.038). The deletion rate of PTEN in invasive B cell lymphoma was 13.6% (32/235), which was not correlated with other clinicopathological features. PIK3CA amplification was negatively correlated with PTEN deletion (P=0.046), and neither was found to be significantly associated with survival.
      Conclusions  PIK3CA amplification and PTEN deletion play a role in the development of invasive B-cell lymphoma, and the former is associated with late stage of the disease.

     

    • HTML全文
    • 参考文献(23)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回